BioCentury | Jan 20, 2021
Politics, Policy & Law

Exit interview: Hahn departs after tumultuous tenure, advocating greater independence for FDA

FDA Commissioner Stephen Hahn presided over the most tumultuous era in FDA’s history, one that will be remembered for the agency’s failure to take aggressive actions at the start of the COVID-19 outbreak,...
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the...
BioCentury | Jan 7, 2021
Management Tracks

Alkermes promotes two to oversee growth plan as CFO Frates departs

As James Frates prepares to depart Alkermes after two decades, the neuroscience company has promoted a pair of executives to lead implementation of the company’s “value enhancement plan” unveiled in December in the wake of...
BioCentury | Jan 7, 2021

Jan. 6 Quick Takes:  Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

Ribometrix, Genentech partner for RNA-targeting small moleculesRibometrix Inc. and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) are partnering to develop small molecules against undisclosed...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...
BioCentury | Dec 12, 2020
Product Development

Ipsen is casting a wider BD net under new CEO Loew

With a pipeline heavy on line extensions and its bestseller headed toward a patent cliff, new Ipsen CEO David Loew is doubling down on the mid-cap biopharma’s commitment to external innovation. But...
BioCentury | Dec 3, 2020

Merck’s divestiture of Moderna stake brought ‘substantial’ return, but shares’ run continued afterward

Merck sold its shares in Moderna at a price at least three times their value at the beginning of 2020, although the biotech’s value has continued to rise since the divestiture’s completion as its COVID-19...
BioCentury | Nov 21, 2020
Politics, Policy & Law

Fate of Trump’s 11th hour drug price rules uncertain

If they withstand withering legal challenges from the biopharmaceutical industry, hospitals and medical groups, and overcome steep logistic obstacles, rules released by the Trump administration Friday...
BioCentury | Nov 20, 2020

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...
Items per page:
1 - 10 of 4098